SunTrust Banks set a $80.00 price target on Walgreens Boots Alliance (NASDAQ:WBA) in a research note released on Thursday, December 21st. The brokerage currently has a hold rating on the pharmacy operator’s stock.
Other analysts have also issued research reports about the stock. Jefferies Group reaffirmed a buy rating and issued a $95.00 price objective on shares of Walgreens Boots Alliance in a research report on Monday, October 2nd. Needham & Company LLC reaffirmed a buy rating and issued a $94.00 price objective on shares of Walgreens Boots Alliance in a research report on Saturday, September 16th. Loop Capital assumed coverage on shares of Walgreens Boots Alliance in a research note on Thursday, August 24th. They issued a buy rating and a $95.00 target price for the company. UBS Group reiterated a buy rating and issued a $96.00 target price (down previously from $97.00) on shares of Walgreens Boots Alliance in a research note on Wednesday, August 23rd. Finally, Mizuho set a $94.00 target price on shares of Walgreens Boots Alliance and gave the stock a buy rating in a research note on Tuesday, October 24th. Nine research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. Walgreens Boots Alliance has an average rating of Buy and an average target price of $86.20.
Walgreens Boots Alliance (NASDAQ:WBA) traded up $0.69 on Thursday, hitting $76.07. 6,458,366 shares of the company were exchanged, compared to its average volume of 6,450,000. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.96 and a quick ratio of 0.47. Walgreens Boots Alliance has a one year low of $63.82 and a one year high of $88.00. The company has a market capitalization of $75,340.00, a price-to-earnings ratio of 21.01, a P/E/G ratio of 1.28 and a beta of 1.22.
Walgreens Boots Alliance (NASDAQ:WBA) last released its quarterly earnings results on Thursday, January 4th. The pharmacy operator reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.01. The company had revenue of $30.74 billion for the quarter, compared to analyst estimates of $30.39 billion. Walgreens Boots Alliance had a net margin of 3.19% and a return on equity of 19.15%. The firm’s revenue was up 7.9% on a year-over-year basis. During the same period last year, the firm earned $1.10 earnings per share. analysts predict that Walgreens Boots Alliance will post 5.67 earnings per share for the current year.
Walgreens Boots Alliance announced that its Board of Directors has authorized a share buyback program on Wednesday, October 25th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the pharmacy operator to purchase shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its stock is undervalued.
In other news, Director William C. Foote sold 2,736 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $67.37, for a total value of $184,324.32. Following the completion of the sale, the director now directly owns 16,415 shares in the company, valued at approximately $1,105,878.55. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John Anthony Lederer purchased 20,000 shares of the stock in a transaction that occurred on Thursday, October 26th. The shares were purchased at an average price of $67.00 per share, with a total value of $1,340,000.00. Following the completion of the acquisition, the director now directly owns 50,000 shares in the company, valued at $3,350,000. The disclosure for this purchase can be found here. Insiders own 14.80% of the company’s stock.
A number of large investors have recently bought and sold shares of the stock. Hudock Capital Group LLC increased its position in Walgreens Boots Alliance by 0.5% during the 2nd quarter. Hudock Capital Group LLC now owns 1,306 shares of the pharmacy operator’s stock valued at $102,000 after purchasing an additional 6 shares during the period. Westside Investment Management Inc. increased its position in Walgreens Boots Alliance by 10.4% during the 2nd quarter. Westside Investment Management Inc. now owns 1,325 shares of the pharmacy operator’s stock valued at $102,000 after purchasing an additional 125 shares during the period. Zions Bancorporation increased its position in Walgreens Boots Alliance by 983.3% during the 3rd quarter. Zions Bancorporation now owns 1,365 shares of the pharmacy operator’s stock valued at $105,000 after purchasing an additional 1,239 shares during the period. IHT Wealth Management LLC increased its position in Walgreens Boots Alliance by 46.3% during the 2nd quarter. IHT Wealth Management LLC now owns 6,946 shares of the pharmacy operator’s stock valued at $135,000 after purchasing an additional 2,199 shares during the period. Finally, Bristlecone Advisors LLC purchased a new position in Walgreens Boots Alliance during the 3rd quarter valued at $135,000. Institutional investors own 61.18% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Walgreens Boots Alliance (WBA) Given a $80.00 Price Target at SunTrust Banks” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/walgreens-boots-alliance-wba-pt-set-at-80-00-by-suntrust-banks.html.
Walgreens Boots Alliance Company Profile
Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. The Company is a global pharmacy-led, health and wellbeing enterprise. Walgreens Boots Alliance operates through three divisions, including Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale. The Company’s products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand).
Receive News & Ratings for Walgreens Boots Alliance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Walgreens Boots Alliance and related companies with MarketBeat.com's FREE daily email newsletter.